BIODESIX INC·4

Feb 11, 6:03 PM ET

O'Kane Kieran 4

4 · BIODESIX INC · Filed Feb 11, 2026

Research Summary

AI-generated summary of this filing

Updated

Biodesix (BDSX) CCO Kieran O'Kane Receives RSUs, Sells 584 Shares

What happened

  • Kieran O'Kane, Chief Commercial Officer of Biodesix (BDSX), had 1,600 restricted stock units (RSUs) convert to common stock on 2026-02-09. Per the filing, 1,600 shares were used to satisfy tax withholding (reported as dispositions of 1,527 and 73 shares), and on 2026-02-10 O'Kane sold 584 shares in the open market at $10.08 per share, generating $5,889 in proceeds.
  • These were not purchases (not a bullish signal): the primary activity was vesting of RSUs and routine sales/withholding related to taxes.

Key details

  • Transaction dates and prices:
    • 2026-02-09: Conversion/settlement of 1,600 RSUs into shares (derivative exercise/conversion).
    • 2026-02-09: 1,527 shares and 73 shares were recorded as disposed (withholding/surrender) in connection with the RSU settlement (reported with $0 proceeds).
    • 2026-02-10: Open-market sale of 584 shares at $10.08 each, proceeds $5,889.
  • Shares owned after transaction: Not specified in the provided excerpt of the filing.
  • Notable footnotes:
    • F1/F4/F6: These were RSUs (each RSU equals one share) that vested according to previously disclosed schedules (some vested quarterly since Feb 8, 2022; others on annual schedule from Feb 8, 2023).
    • F2/F3: Shares were automatically sold/withheld to cover taxes upon vesting. The filing notes sales by the issuer's broker at prices ranging $9.94–$10.21; the reported $10.08 is a weighted average for the reported sale(s).
    • F5: Share counts were adjusted for a 1-for-20 reverse stock split effective Sept 15, 2025.
  • Timeliness: Reported on 2026-02-11 for transactions on 2026-02-09/10 — the Form 4 was filed within the standard two-business-day window (not reported late).

Context

  • These entries reflect RSU vesting and routine tax-withholding-related dispositions. For derivative/RSU activity, the filing shows conversion of awards into shares and immediate withholding/sales to cover tax obligations (i.e., a cashless/net settlement), not an independent investment decision.

Insider Transaction Report

Form 4
Period: 2026-02-09
O'Kane Kieran
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-09+1,6009,469 total
  • Sale

    Common Stock

    [F2][F3]
    2026-02-10$10.08/sh584$5,8898,885 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F4]
    2026-02-09730 total
    Common Stock (73 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F5][F6]
    2026-02-091,5271,526 total
    Common Stock (1,527 underlying)
Footnotes (6)
  • [F1]Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  • [F2]These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
  • [F3]The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date.
  • [F5]These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
  • [F6]These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane|2026-02-11

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4